Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 352.65 INR 4.85% Market Closed
Market Cap: 423.4B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biocon Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Selling, General & Administrative
-â‚ą30.1B
CAGR 3-Years
-18%
CAGR 5-Years
-18%
CAGR 10-Years
-20%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Selling, General & Administrative
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Selling, General & Administrative
-â‚ą3.1m
CAGR 3-Years
-10%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Selling, General & Administrative
-â‚ą101.9m
CAGR 3-Years
-15%
CAGR 5-Years
-15%
CAGR 10-Years
-5%
Hester Biosciences Ltd
NSE:HESTERBIO
Selling, General & Administrative
-â‚ą635.8m
CAGR 3-Years
-13%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Selling, General & Administrative
-â‚ą1.5B
CAGR 3-Years
3%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
423.4B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
451.57 INR
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Selling, General & Administrative?
Selling, General & Administrative
-30.1B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Selling, General & Administrative amounts to -30.1B INR.

What is Biocon Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-20%

Over the last year, the Selling, General & Administrative growth was -29%. The average annual Selling, General & Administrative growth rates for Biocon Ltd have been -18% over the past three years , -18% over the past five years , and -20% over the past ten years .

Back to Top